{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Rallybio Corporation"},"Symbol":{"label":"Symbol","value":"RLYB"},"Address":{"label":"Address","value":"234 CHURCH STREET,SUITE 1020, NEW HAVEN, Connecticut, 06510, United States"},"Phone":{"label":"Phone","value":"+1 203 859-3820"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns."},"CompanyUrl":{"label":"Company Url","value":"https://www.rallybio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Michael Bombara","title":"Head-Clinical Operations"},{"name":"Stephen Uden","title":"President, Chief Executive Officer & Director"},{"name":"Steven W. Ryder","title":"Chief Medical Officer"},{"name":"Zhiliang Cheng","title":"Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}